Zachary R.
About Zachary R.
Zachary R. is the Co-Founder and Chief Executive Officer of Sigma Genetics, Inc., where he has worked since 2018. He has a background in business development and research, with previous roles at Altoida, Inc., Pharmagellan, and Icahn School of Medicine at Mount Sinai.
Work at Sigma Genetics
Zachary R. serves as the Co-Founder and Chief Executive Officer of Sigma Genetics, Inc. since 2018. In this role, he has focused on advancing cellular product manufacturing through innovative gene delivery technologies. He developed the Magnetoporator™ gene delivery platform, which employs magnetic fields for efficient gene delivery. Under his leadership, Sigma Genetics has made strides in the development of non-viral gene delivery systems aimed at manufacturing life-saving therapies.
Previous Experience in Business Development
Before his tenure at Sigma Genetics, Zachary R. worked at Altoida, Inc. as the Director of Business Development from 2017 to 2019. His role involved strategic planning and partnership development to enhance the company's market presence. Additionally, he served as an Associate Consultant at Pharmagellan from 2016 to 2018, where he contributed to consulting projects that supported pharmaceutical and biotechnology companies.
Research Background
Zachary R. has a solid research background, having worked as a Senior Associate Researcher at the Icahn School of Medicine at Mount Sinai from 2011 to 2016. His work was affiliated with Columbia University Medical Center, where he engaged in research that contributed to advancements in medical science. He also held a position as an Assistant Editor at the Harvard University Kennedy School of Government in 2011 for 11 months, focusing on publications related to science and international affairs.
Education and Expertise
Zachary R. holds a Bachelor of Arts degree in Biological Anthropology from Drew University. He furthered his education by obtaining a Master of Arts degree in Biotechnology and Cancer Genetics from Columbia University Graduate School of Arts and Sciences. His academic background supports his expertise in gene delivery systems, particularly in the context of developing therapies that address critical health needs.